ABT-239 is more active at the human H3 receptor than comparable agents such as thioperamide, ciproxifan, and cipralisant.
ABT-239 je aktivniji na ljudskom H3 receptoru od sličnih liganda, npr. tioperamida, ciproksifana, i cipralisanta.